Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase Mutant Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel carbonyl reductase mutant enables high-purity chiral intermediate synthesis with reduced solvent waste and cost for pharmaceutical supply chains.
Patent CN104099305A reveals stable CgKR1 mutants for Clopidogrel intermediates. Enhances purity and supply chain reliability for global pharmaceutical manufacturing.